FAQ on Tonix Pharmaceuticals' Single-Dose Mpox Vaccine Data Presentation
Summary
Tonix Pharmaceuticals presented promising preclinical data on its single-dose mpox vaccine, TNX-801, at the World Vaccine Congress, highlighting its efficacy and potential for broad application in global health emergencies.
What is TNX-801?
TNX-801 is a single-dose mpox vaccine candidate developed by Tonix Pharmaceuticals, shown to protect animals, including immunocompromised subjects, against mpox and rabbitpox with durable protection lasting six months.
Why is TNX-801 significant?
TNX-801 aligns with the World Health Organization’s preferred target profile for mpox vaccines, offering potential for broad application in current and future mpox outbreaks declared as global health emergencies.
How does TNX-801 work?
TNX-801 is a minimally replicative live-virus vaccine that has demonstrated efficacy in preclinical studies by providing durable protection against mpox and rabbitpox.
Who presented the data on TNX-801?
Tonix Pharmaceuticals presented the positive preclinical data on TNX-801 at the World Vaccine Congress Washington 2025.
When was the data on TNX-801 presented?
The data was presented at the World Vaccine Congress Washington 2025, though the exact date is not specified in the content.
Where can I find more information about TNX-801?
More information can be found in the full press release available at https://ibn.fm/Rtlzx and on Tonix Pharmaceuticals’ website at www.TonixPharma.com.
What are the implications of TNX-801’s success?
The success of TNX-801 could lead to a new, effective vaccine option for mpox, addressing a critical need in global health emergencies and potentially preventing future outbreaks.
How does TNX-801 compare to other mpox vaccines?
While the content does not provide a direct comparison to other mpox vaccines, TNX-801’s single-dose regimen and efficacy in immunocompromised subjects highlight its potential advantages.
What should people know about Tonix Pharmaceuticals?
Tonix Pharmaceuticals is a fully-integrated biopharmaceutical company focused on transforming therapies for pain management and modernizing solutions for public health challenges, with a diverse development portfolio including CNS disorders, immunology, rare diseases, and infectious diseases.
Who do I contact for more information about Tonix Pharmaceuticals?
For more information, visit Tonix Pharmaceuticals’ website at www.TonixPharma.com or check the latest news and updates relating to TNXP in the company’s newsroom at https://ibn.fm/TNXP.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 120204